RxDoctor Payments DataLook up a doctor →

Richard Silton, MD

Allergy & Immunology · Charlotte, NCNPI 1225063431

Payments from drug & device makers

$11,770in general payments, 2019–2025

Across 564 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • CSL Behring$869
  • Takeda Pharmaceuticals U.S.A., Inc.$667
  • Pfizer$638
  • plus $5K from 30 others

What the payments were for

  • Consulting fees$230%
  • Food & beverage$11,64999%
  • Education$981%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,770 in reported general payments places this provider in the 65th percentile of 140 allergy & immunology providers in North Carolina.

See all allergy & immunology providers in North Carolina

Medicare billing

Part B allowed, 2024
$188,734
Medicare patients
152
Services billed
6,730

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TakhzyroLanadelumab-Flyo35$1,411,543
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5013$145,891
XolairOmalizumab27$110,664
Breo ElliptaFluticasone/Vilanterol50$35,111
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$19,415
SymbicortBudesonide/Formoterol Fumarate38$12,014
Qvar RedihalerBeclomethasone Dipropionate13$5,853
Epinephrine32$4,851
Arnuity ElliptaFluticasone Furoate17$4,021
Azelastine Hcl105$3,212
Albuterol Sulfate HfaAlbuterol Sulfate90$2,414
Fluticasone Propionate93$2,112
Ventolin HfaAlbuterol Sulfate20$1,072
Wixela InhubFluticasone Propion/Salmeterol19$881
Ipratropium Bromide20$850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Takhzyro$667$1,411,54335 claims
CSL BehringPrivigen$869$145,89113 claims
GSKBreo Ellipta, Trelegy Ellipta, Arnuity Ellipta$1,393$58,54897 claims
AstraZenecaSymbicort$2,439$12,01438 claims
Teva Pharmaceuticals USA, Inc.Qvar Redihaler$83$5,85313 claims
Hikma Pharmaceuticals USAEpinephrine$19$4,85132 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 140 allergy & immunology providers in North Carolina.

Other allergy & immunology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →